Thymosin Alpha-1 vs Thymulin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Thymosin Alpha-1
Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.
Full details →Thymulin
Thymulin (Facteur Thymique Sérique) is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells. It plays important roles in T-cell differentiation and immune system maturation.
Full details →Side-by-Side Comparison
| Aspect | Thymosin Alpha-1 | Thymulin |
|---|---|---|
| Dose Range | 1.6 mg–3.2 mg | 100 mcg–400 mcg |
| Frequency | Less than daily | 1x daily |
| Cycle Length | 4–12 weeks | 4–8 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Enhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes. | Requires zinc for biological activity. Promotes T-cell differentiation, modulates cytokine production, and influences neuroendocrine function. Levels decline significantly with age. |
| Typical Dosage | Clinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary. | Research protocols vary. Often studied alongside zinc supplementation. Typical research doses in the microgram range. |
| Administration | Subcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols. | Subcutaneous or intramuscular injection in research settings. Requires adequate zinc status for activity. |
| Side Effects | Generally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue. | Limited data on exogenous administration. Theoretical effects on immune function require monitoring. |
| Best For |
Key Differences
Unique to Thymosin Alpha-1:
Unique to Thymulin:
Key Studies
Thymosin Alpha-1
- Aging and Thymosin Alpha-1.
International journal of molecular sciences, 2025
- Phenotypic drug discovery: a case for thymosin alpha-1.
Frontiers in medicine, 2024
- The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.
Inflammopharmacology, 2023
Thymulin
- Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy.
Nature communications, 2026
- Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice.
International journal of immunopathology and pharmacology, 2021
- Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma.
Science advances, 2020
Ready to Learn More?
Looking for trusted sources?